Innovative “SDM Circles” program integrates restorative justice practices to address medical mistrust and improve lung cancer screening among Black communities WASHINGTON, DC – February 12, 2026 – GO2 for Lung Cancer (GO2) has received support from AstraZeneca US through its 2025 [...]
Today marks a huge step for improving the lives of everyone affected by lung cancer. S. 1157, the Women and Lung Cancer Research and Preventive Services Act, advances with a favorable vote in the Senate Health, Education, Labor, and Pensions (HELP) [...]
On December 17, 2025, the U.S. Food and Drug Administration (FDA) approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Rybrevant (amivantamab) that the FDA previously approved for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have an [...]
We are finally seeing a growing drumbeat of reports about lung cancer screening that reflect the real-world experiences of people facing this disease. These reports confirm what doctors, patients, and advocates like GO2 for Lung Cancer have been saying for [...]
Did you know? HER2 is a gene found in cells that is important for cell growth and survival. You may also sometimes see HER2 referred to by the name ERBB-2. In some people, the HER2 gene begins to change [...]
WASHINGTON, October 30, 2025 — GO2 for Lung Cancer (GO2) announced that David A. Feldman has been elected to its board of directors. Mr. Feldman is an experienced attorney with expertise in investigations, litigation, compliance, and risk management. He currently serves as Deputy Director [...]
By Andrew Ciupek and Brittney Nichols The GO2 team attended the 2025 World Conference on Lung Cancer, where researchers from around the world shared the latest findings and breakthroughs in lung cancer research. Here are some of the key updates [...]
On October 2, 2025, the U.S. Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) or Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as maintenance therapy for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease [...]
It’s heartbreaking that our elected leaders can’t find common ground on something as important as the health and well-being of the cancer community. A government shutdown once again puts vital lung cancer research and access to care at risk. This [...]
On September 19, 2025, the U.S. Food and Drug Administration (FDA) approved a new administration method for Keytruda (pembrolizumab). Under the new approval, Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) can now be given by subcutaneous injection, commonly known as a shot, [...]